Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.68
Nov 17 • 3:57 PM ET Dollar change-0.02 Percentage change(-1.18%)
Aftermarket Close
1.69
Aftermarket • 5:00 PM ET Dollar change+0.01 Percentage change(0.60%)
Index
-
Market Cap
1.57M
Enterprise Value
-2.83M
Income
-11.32M
Sales
0.00M
Book/sh
6.65
Cash/sh
4.75
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
7
IPO
Nov 14, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.25
P/C
0.35
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
10.47
Current Ratio
10.47
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-102.99
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
16.31% 35.60%
Sales past 3/5Y
- -
EPS Y/Y TTM
81.76%
Sales Y/Y TTM
-
EPS Q/Q
97.02%
Sales Q/Q
-
Insider Own
0.06%
Insider Trans
0.00%
Inst Own
5.69%
Inst Trans
-0.83%
ROA
-206.89%
ROE
-404.03%
ROIC
-181.51%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-23.20%
SMA50
-48.95%
SMA200
-91.21%
Trades
Shs Outstand
0.94M
Shs Float
0.55M
52W High
179.19 -99.06%
52W Low
1.62 4.02%
Volatility
13.19% 10.80%
ATR (14)
0.32
RSI (14)
28.67
Beta
0.04
Rel Volume
0.05
Avg Volume
481.08K
Volume
21,774
Perf Week
-21.58%
Perf Month
-36.84%
Perf Quarter
-74.07%
Perf Half Y
-86.27%
Perf YTD
-94.90%
Perf Year
-96.58%
Perf 3Y
-99.12%
Perf 5Y
-99.92%
Perf 10Y
-
Prev Close
1.70
Price
1.68
Change %
-1.18%
Consensus
Hold
Avg. Price Target
$486.00
Implied Upside
+28,828.6%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2025Upgrade
DD. Boral Capital
Hold → Buy$20+1,090.5%
Feb 12, 2021Initiated
LLadenburg Thalmann
Buy$7+316.7%
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
PresidentMr. Gregory D. Gorgas M.B.A.
CFOMr. Mark E. Spring CPA
Senior VP & Chief Scientific OfficerDr. Andrew Yates Ph.D.
Chief Medical OfficerDr. Steven D. Reich M.D.
Senior Vice President of FinanceMr. Jason H. Baybutt